Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
This is a Phase 3 multicenter, double-blind, double-dummy, randomized study. Only subjects with PV who have received HU for at least 12 weeks, have been receiving a stable dose before screening, and still have symptoms related to PV will be enrolled.
Subjects will be randomized (1:1) to 1 of 2 treatment arms:
A: ruxolitinib and HU-placebo B: HU and ruxolitinib-placebo
Subjects randomized to either arm may be eligible to transition to open-label ruxolitinib after Week 16.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must currently be reporting symptoms while on a stable dose of HU monotherapy and be eligible to continue HU on study after randomization.
Before screening, the subject must have been receiving HU for at least 12 weeks AND be receiving a stable dose.
Subjects must meet baseline symptom criteria
Subjects should meet at least 1 of the following criteria:
* No more than 2 phlebotomies within the 6 months before screening OR
* No palpable splenomegaly.
Subjects must have a hematocrit that can be controlled within 35% to 48% (inclusive) before randomization.
You may not be if
Subjects with inadequate liver or renal function at screening.
Subjects with clinically significant infection that requires therapy
Subjects with known active hepatitis A, B, or C at screening or with known HIV positivity.
Subjects with an active malignancy over the previous 2 years
Subjects with clinically significant cardiac disease (Class III or IV).